9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Transient commensal clonal interactions can drive tumor metastasis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The extent and importance of functional heterogeneity and crosstalk between tumor cells is poorly understood. Here, we describe the generation of clonal populations from a patient-derived ovarian clear cell carcinoma model which forms malignant ascites and solid peritoneal tumors upon intraperitoneal transplantation in mice. The clonal populations are engineered with secreted Gaussia luciferase to monitor tumor growth dynamics and tagged with a unique DNA barcode to track their fate in multiclonal mixtures during tumor progression. Only one clone, CL31, grows robustly, generating exclusively malignant ascites. However, multiclonal mixtures form large solid peritoneal metastases, populated almost entirely by CL31, suggesting that transient cooperative interclonal interactions are sufficient to promote metastasis of CL31. CL31 uniquely harbors ERBB2 amplification, and its acquired metastatic activity in clonal mixtures is dependent on transient exposure to amphiregulin, which is exclusively secreted by non-tumorigenic clones. Amphiregulin enhances CL31 mesothelial clearance, a prerequisite for metastasis. These findings demonstrate that transient, ostensibly innocuous tumor subpopulations can promote metastases via “hit-and-run” commensal interactions.

          Abstract

          Cooperative interactions among tumor cells may have important implications for metastasis. Here, the authors examined the spatio-temporal nature of interactions among clonal populations of ovarian carcinoma cells and found that transient interactions cells can promote metastases via commensal interactions.

          Related collections

          Most cited references64

          • Record: found
          • Abstract: found
          • Article: not found

          Signatures of mutational processes in human cancer

          All cancers are caused by somatic mutations. However, understanding of the biological processes generating these mutations is limited. The catalogue of somatic mutations from a cancer genome bears the signatures of the mutational processes that have been operative. Here, we analysed 4,938,362 mutations from 7,042 cancers and extracted more than 20 distinct mutational signatures. Some are present in many cancer types, notably a signature attributed to the APOBEC family of cytidine deaminases, whereas others are confined to a single class. Certain signatures are associated with age of the patient at cancer diagnosis, known mutagenic exposures or defects in DNA maintenance, but many are of cryptic origin. In addition to these genome-wide mutational signatures, hypermutation localized to small genomic regions, kataegis, is found in many cancer types. The results reveal the diversity of mutational processes underlying the development of cancer with potential implications for understanding of cancer etiology, prevention and therapy.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Genes that mediate breast cancer metastasis to the brain.

            The molecular basis for breast cancer metastasis to the brain is largely unknown. Brain relapse typically occurs years after the removal of a breast tumour, suggesting that disseminated cancer cells must acquire specialized functions to take over this organ. Here we show that breast cancer metastasis to the brain involves mediators of extravasation through non-fenestrated capillaries, complemented by specific enhancers of blood-brain barrier crossing and brain colonization. We isolated cells that preferentially infiltrate the brain from patients with advanced disease. Gene expression analysis of these cells and of clinical samples, coupled with functional analysis, identified the cyclooxygenase COX2 (also known as PTGS2), the epidermal growth factor receptor (EGFR) ligand HBEGF, and the alpha2,6-sialyltransferase ST6GALNAC5 as mediators of cancer cell passage through the blood-brain barrier. EGFR ligands and COX2 were previously linked to breast cancer infiltration of the lungs, but not the bones or liver, suggesting a sharing of these mediators in cerebral and pulmonary metastases. In contrast, ST6GALNAC5 specifically mediates brain metastasis. Normally restricted to the brain, the expression of ST6GALNAC5 in breast cancer cells enhances their adhesion to brain endothelial cells and their passage through the blood-brain barrier. This co-option of a brain sialyltransferase highlights the role of cell-surface glycosylation in organ-specific metastatic interactions.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis.

              Circulating tumor cell clusters (CTC clusters) are present in the blood of patients with cancer but their contribution to metastasis is not well defined. Using mouse models with tagged mammary tumors, we demonstrate that CTC clusters arise from oligoclonal tumor cell groupings and not from intravascular aggregation events. Although rare in the circulation compared with single CTCs, CTC clusters have 23- to 50-fold increased metastatic potential. In patients with breast cancer, single-cell resolution RNA sequencing of CTC clusters and single CTCs, matched within individual blood samples, identifies the cell junction component plakoglobin as highly differentially expressed. In mouse models, knockdown of plakoglobin abrogates CTC cluster formation and suppresses lung metastases. In breast cancer patients, both abundance of CTC clusters and high tumor plakoglobin levels denote adverse outcomes. Thus, CTC clusters are derived from multicellular groupings of primary tumor cells held together through plakoglobin-dependent intercellular adhesion, and though rare, they greatly contribute to the metastatic spread of cancer. Copyright © 2014 Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                joan_brugge@hms.harvard.edu
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                16 November 2020
                16 November 2020
                2020
                : 11
                : 5799
                Affiliations
                [1 ]GRID grid.38142.3c, ISNI 000000041936754X, Department of Cell Biology, , Harvard Medical School, ; Boston, MA 02115 USA
                [2 ]GRID grid.5288.7, ISNI 0000 0000 9758 5690, Department of Molecular and Medical Genetics, , Oregon Health & Science University Portland, ; Portland, OR 97239-3098 USA
                [3 ]GRID grid.240145.6, ISNI 0000 0001 2291 4776, Department of Genetics, , University of Texas MD Anderson Cancer Center, ; Houston, TX 77030 USA
                [4 ]GRID grid.32224.35, ISNI 0000 0004 0386 9924, Vincent Center for Reproductive Biology and Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, ; Boston, MA 02114 USA
                [5 ]GRID grid.38142.3c, ISNI 000000041936754X, Harvard Medical School, ; Boston, MA 02115 USA
                [6 ]GRID grid.215654.1, ISNI 0000 0001 2151 2636, Arizona Cancer Evolution Center and Department of Psychology, , Arizona State University, ; Tempe, AZ 85281 USA
                [7 ]GRID grid.5386.8, ISNI 000000041936877X, Department of Pathology and Laboratory Medicine, , Weill Cornell Medicine, ; New York, NY USA
                [8 ]GRID grid.415436.1, ISNI 0000 0004 0443 7314, New York Presbyterian-Brooklyn Methodist Hospital, ; Brooklyn, NY 11215 USA
                [9 ]GRID grid.492659.5, Caris Life Sciences, ; Phoenix, AZ 85040 USA
                [10 ]GRID grid.5288.7, ISNI 0000 0000 9758 5690, Department of Cell, Developmental and Cancer Biology, , Oregon Health and Science University Knight Cancer Institute, ; Portland, OR 97239-3098 USA
                [11 ]GRID grid.38142.3c, ISNI 000000041936754X, Rodent Histopathology Core, Harvard Medical School, ; Boston, MA 02115 USA
                [12 ]GRID grid.10306.34, ISNI 0000 0004 0606 5382, Present Address: Cancer, Ageing and Somatic Mutation, Wellcome Trust Sanger Institute, ; Hinxton, UK
                [13 ]GRID grid.239552.a, ISNI 0000 0001 0680 8770, Present Address: The Center for Applied Genomics, , Children’s Hospital of Philadelphia, ; Pennsylvania, PA 19104 USA
                [14 ]GRID grid.17635.36, ISNI 0000000419368657, Present Address: Department of Pharmacology, Masonic Cancer Center, , University of Minnesota Medical School, ; Minneapolis, MN 55455 USA
                [15 ]GRID grid.413480.a, ISNI 0000 0004 0440 749X, Present Address: Department of Medicine, , Dartmouth-Hitchcock Medical Center, ; Lebanon, NH 03766 USA
                [16 ]GRID grid.34477.33, ISNI 0000000122986657, Present Address: Department of Obstetrics & Gynecology, , University of Washington, ; Seattle, WA 98195 USA
                [17 ]Present Address: Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Nonnenwald 2, 82377 Penzberg, Germany
                [18 ]GRID grid.5386.8, ISNI 000000041936877X, Present Address: Meyer Cancer Center, Weill Cornell Medicine, ; New York, NY USA
                [19 ]GRID grid.5386.8, ISNI 000000041936877X, Present Address: The Biochemistry, Structural, Developmental, Cell and Molecular Biology Allied PhD Program, , Weill Cornell Medicine, ; New York, NY 10065 USA
                [20 ]GRID grid.266902.9, ISNI 0000 0001 2179 3618, Present Address: Department of Pathology, , University of Oklahoma Health Sciences Center, ; Oklahoma City, OK 73104 USA
                Author information
                http://orcid.org/0000-0002-1317-7353
                http://orcid.org/0000-0002-5838-5535
                http://orcid.org/0000-0002-5352-0742
                http://orcid.org/0000-0001-9489-8699
                http://orcid.org/0000-0001-6419-2513
                http://orcid.org/0000-0002-0144-9614
                http://orcid.org/0000-0002-2547-4814
                Article
                19584
                10.1038/s41467-020-19584-1
                7669858
                33199705
                ab9ba9d2-7e10-468a-904d-696bec6bc7c9
                © The Author(s) 2020

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 1 July 2020
                : 22 October 2020
                Funding
                Funded by: FundRef https://doi.org/10.13039/100000054, U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI);
                Award ID: CA181543
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/100005984, Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (Dr. Miriam & Sheldon G. Adelson Medical Research Foundation);
                Categories
                Article
                Custom metadata
                © The Author(s) 2020

                Uncategorized
                tumour heterogeneity,mechanisms of disease,phylogenetics,ovarian cancer,metastasis
                Uncategorized
                tumour heterogeneity, mechanisms of disease, phylogenetics, ovarian cancer, metastasis

                Comments

                Comment on this article